Literature DB >> 33172774

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Nattakorn Dhiantravan1, John Violet2, Renu Eapen3, Omar Alghazo4, Mark Scalzo5, Price Jackson6, Simon P Keam7, Catherine Mitchell8, Paul J Neeson9, Shahneen Sandhu10, Scott G Williams2, Daniel Moon11, Nathan Lawrentschuk12, Arun Azad10, Michael S Hofman13, Declan G Murphy14.   

Abstract

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177-radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33172774     DOI： 10.1016/j.euf.2020.09.021

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  7 in total

1.  Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.

Authors:  Shahneen Sandhu; Christina Guo; Michael S Hofman
Journal:  J Nucl Med       Date:  2021-08-12       Impact factor: 11.082

2.  Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.

Authors:  Michael S Hofman
Journal:  J Nucl Med       Date:  2021-08-12       Impact factor: 11.082

Review 3.  Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective.

Authors:  Thomas S C Ng; Xin Gao; Keyan Salari; Dimitar V Zlatev; Pedram Heidari; Sophia C Kamran
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

Review 4.  Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.

Authors:  Kristin A Plichta; Stephen A Graves; John M Buatti
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

5.  Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended or Not. The Referee Point of View.

Authors:  Marlon Perera; Karim A Touijer
Journal:  Eur Urol Open Sci       Date:  2022-08-19

Review 6.  Prognostic and Theranostic Applications of Positron Emission Tomography for a Personalized Approach to Metastatic Castration-Resistant Prostate Cancer.

Authors:  Luca Filippi; Viviana Frantellizzi; Agostino Chiaravalloti; Mariano Pontico; Maria Silvia De Feo; Ferdinando Corica; Melissa Montebello; Orazio Schillaci; Giuseppe De Vincentis; Oreste Bagni
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

7.  Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?

Authors:  William John Yaxley; Rhiannon McBean; David Wong; David Grimes; Paul Vasey; Mark Frydenberg; John William Yaxley
Journal:  Investig Clin Urol       Date:  2021-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.